Article
The clinical efficacy of combinatorial therapy of EGFR-TKI and crizotinib in overcoming MET amplification-mediated resistance from prior EGFR-TKI therapy.
Lung cancer (Amsterdam, Netherlands) - 1 Aug 2020
Wang Yubo, Tian Panwen, Xia Lei, Li Li, Han Rui, Zhu Mengxiao, Lizaso Analyn, Qin Tian, Li Min, Yu Bing, Mao Xinru, Han-Zhang Han, He Yong
Abstract excerpt
BACKGROUND: MET amplification is one of the EGFR-independent mechanisms of EGFR tyrosine kinase inhibitor (TKI) resistance. Combinatorial therapy of EGFR-TKI and crizotinib has been explored as a strategy to overcome resistance by simultaneously targeting both EGFR and MET pathways; however, no consensus still exists on the optimal combination regimen with the most benefit. METHODS: Retrospective analysis was...
Topics
- Crizotinib
- Drug Resistance, Neoplasm
- ErbB Receptors
- Humans
- Lung Neoplasms
- Mutation
- Protein Kinase Inhibitors
- Proto-Oncogene Proteins c-met
- Retrospective Studies
- Treatment Outcome